These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22531532)

  • 1. Synchronous bilateral medullary carcinoma of breast: is it metastasis or second primary?
    ; Permi HS; Kishan Prasad HL; Mohan R; Shetty KJ; Patil C
    J Cancer Res Ther; 2012; 8(1):129-31. PubMed ID: 22531532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.
    Heron DE; Komarnicky LT; Hyslop T; Schwartz GF; Mansfield CM
    Cancer; 2000 Jun; 88(12):2739-50. PubMed ID: 10870056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer].
    Zhang P; Xu BH; Ma F; Li Q
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):128-31. PubMed ID: 20403244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral breast cancer.
    Gogas J; Markopoulos C; Skandalakis P; Gogas H
    Am Surg; 1993 Nov; 59(11):733-5. PubMed ID: 8239195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid metastasis from breast carcinoma resembling medullary thyroid carcinoma.
    Slipac J; Janjanin S; Ljepava D; Hutinec Z; Bence-Zigman Z
    Coll Antropol; 2012 Nov; 36 Suppl 2():63-6. PubMed ID: 23397757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor changes in metachronous breast tumors--our experience of 10 years.
    Bhullar JS; Unawane A; Subhas G; Poonawala H; Dubay L; Ferguson L; Goriel Y; Jacobs MJ; Kolachalam RB; Silapaswan S; Mittal VK
    Am J Surg; 2012 Mar; 203(3):405-9; discussion 409. PubMed ID: 22206855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary breast carcinoma: a case report with cytological features and histological confirmation.
    Aouni NE; Athanasiou A; Mansouri D; Marsiglia H; Mathieu MC; Suciu V; Vielh P
    Diagn Cytopathol; 2006 Oct; 34(10):701-3. PubMed ID: 16955478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bilateral carcinoma of the breast].
    Napolitano L; Grossi S; Cianchetti E
    Ann Ital Chir; 1993; 64(6):665-8; discussion 668-9. PubMed ID: 8080156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-needle aspiration cytology of medullary breast carcinoma: report of two cases and review of the literature with emphasis on differential diagnosis.
    Racz MM; Pommier RF; Troxell ML
    Diagn Cytopathol; 2007 Jun; 35(6):313-8. PubMed ID: 17497662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population.
    Wadasadawala T; Lewis S; Parmar V; Budrukkar A; Gupta S; Nair N; Shet T; Badwe R; Sarin R
    Clin Breast Cancer; 2018 Aug; 18(4):e727-e737. PubMed ID: 29254601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
    Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.